MicroRNAs in carcinogenesisHagan J.P. · Croce C.M.
Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH (USA)
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
MicroRNAs are an abundant class of noncoding RNAs, typically 20–23 nucleotides in length that are often evolutionarily conserved in metazoans and expressed in a cell and tissue specific manner. MicroRNAs exert their gene regulatory activity primarily by imperfectly base pairing to the 3′ UTR of their target mRNAs, leading to mRNA degradation or translational inhibition. In cancer, microRNAs are often dysregulated with their expression patterns being correlated with clinically relevant tumor characteristics. Recently, microRNAs were shown to be directly involved in cancer initiation and progression. This review focuses primarily on emerging developments in the microRNA field that impact our understanding of how these molecules contribute to carcinogenesis.
© 2007 S. Karger AG, Basel
Note added in proof
Since the acceptance of this review, many important papers have been published in relation to mammalian microRNA biology. For brevity’s sake, a few noteworthy studies in the context of this review will be mentioned. MicroRNA-125a/b whose expression is frequently lost or reduced in breast cancer has been reported to regulate the important oncogenes ERBB2 and ERBB3 (Scott et al., 2007). Two research groups have published a mouse knockout of miR-155, demonstrating that this microRNA is required for normal immune function (Rodriguez et al., 2007; Thai et al., 2007). Similarly, a mouse knockout of miR-1-2 is characterized by cardiac defects, leading to 50% lethality by weaning age (Zhao et al., 2007). Lastly, mouse screens that involve mapping of retroviral integration sites that lead to T-cell lymphoma development have identified the activation of two separate microRNA clusters, miR-17/18/19a/ 20a/19b-1/92-1 or miR-106a/20b/19b-2/92-2/ 363, as the causative event (Wang et al., 2006; Lum et al., 2007). These results confirm the significance of microRNAs in normal mammalian development and in cancer.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.